Agreed - good luck Petros

My wife is the type of thoughtful physician I aspire to be She’s working urgent care tonight and seeing kids who are too sick to go trick-or-treating so she brought them toys to take home in the hopes they don’t feel too left out Talk about putting care in healthcare ❤️

I have know Monty for a decade now. He is a wonderful colleague, oncologist and now friend. He always has time for colleagues and in particular trainees. His commitment to them and his patients shines through. I strongly recommend Monty for the ASCO board. @OpenMedKate @StephenVLiu @brian_rini @kor_shah @OpenMedInsights @OpenMedicineHQ @OncBrothers @StephenVLiu @AlanBryce9 @OncoThor @TylerSbrt

An effective Board of Directors can shape an organization. @montypal has the vision and leadership to guide and grow ASCO nationally and internationally.

So many incredible folks on this list - many of whom are treasured friends. To @shilpaonc & @PBarataMD, now running phase III trials and making sea changes in how we treat #genitourinary cancers, congratulations! To @curijoey, the 2027-2028 @myESMO President, congratulations! To @GregoryAVidal, who I have exchanged ideas over Lou Malnati's pizza with at many an @ASCO, congratulations! And to @NazliDizman, what more can I say! Achieving the #FASCO status within your first 3 months as faculty at @DanaFarber isan incredible feat & a sign of what's to come! Congrats to everyone on this list (@Joshua_Reuss, @ryangentzler, @VjChaudharyMD & everyone else!) & thank you for your commitment to @ASCO!

@ASCO elections are open now until Dec 2nd! This year proud to support friends @montypal @PGrivasMDPhD @wandering_gu Todd Morgan @AshleySumrallMD -- and @teekayowo for President Elect! Vote for ASCO asco.org/election @OncoAlert @WomeninOnc

Just happened today👏🎉👉 @FDA approved Talazoparib + enzalutamide for pts with HRRm positive mAPMS/mHSPC #prostatecancer FDA Link👉 l1nq.com/ltlq6jk 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @DanaFarber_GU

SWOG S2200: Cabozantinib with or Without Atezolizumab in Metastatic Papillary RCC. Presented by @maughanonc @huntsmancancer. #ESMO26 written coverage by @rksayyid @UAUrology > bit.ly/4yLiKH1 #KidneyCancer #RCC #Immunotherapy @myESMO @SWOG

VOLGA explored short periods of EV (3 cycles) with duvalumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVD was associated with better EFS + OS vs cystectomy alone (0.51 and 0.58 respectively). pCR 40-45% with ctDNA clearance rates of 60%. High rates of adjuvant IO therapy uptake and low rates of neuropathy suggest potential advantages of this approach which focuses the ADC in the neoadjuvant phase. It’s likely to be attractive for patients.

Leaving Madrid w so many good moments #ESMO26 @myESMO - brain exploding w data & new trials for our patients, feet sore, heart full after connecting w/ old & new friends across the world. Was an incredibly hard wk w loss of Rachna — we continue the hard & good work. @OncoAlert

Gorgeous AM in Retiro Park ahead of exciting RCC updates #ESMO26: 🌟final KN564 @DrChoueiri 🌟PROs of RAMPART 🌟CA-IX PET 🌟cabo/atezo in metastatic papillary RCC @maughanonc 🌟EVP in RMC 🌟LACO-Stim CART 🌟KIM-1 @VincentWenxinXu 🌟PDL1 #CARE1 🌟LITESPARK011 QoL @DrDanielHeng

Brilliant talks from @AlbigesL, @KoenvdMijn, @YujiMiura5 & @BraunMDPhD at #ESMO26 highlighting novel therapies for #kidneycancer. Lots of perspective shifting evidence & discussion - I’m walking away with (1) the thought that we could still optimize ADCs for RCC despite multiple failed attempts (need to watch the talk!) and (2) the need to explore “smarter TILs”. @OncoAlert

Rigorous biomarker trials are extremely difficult to design. @AlbigesL is doing it! Looking forward to seeing the results at a future meeting. #ESMO26 @OncoAlert

In the absence of CNS irAEs I have not previously thought much about it. I think most of us under appreciate the cardiac and neuro consequences of long term inflammation from IO. Agree we should focus more on this.

@CPRT65 Camillo Porta and @sophiemerrick1 for great PRO work and discussion of IO AEs and potential long term side effects. The possibility of persistent worsening “neurocognitive function” must now be discussed with patients who are engaging with adjuvant IO. ESMO26

Preston Wiley starting off #WSAUA26 off strong presenting our work on robotic vs open RPLND! 🌟 No concerning oncologic signals 🌟 Shorter LOS 💡 more work ahead!

Great presentation by @maughanonc! SWOG S2200: cabozantinib + atezolizumab showed a PFS signal vs cabozantinib in metastatic papillary RCC (HR 0.46). Only 33 eligible patients after early closure for slow accrual. Small but important! #ESMO26 @oncoalert @myESMO

#PAPMET2 trial @maughanonc although closed early d/t slow enrollment, still very meaningful to show more data to support IO/TKI preferred over TKI in papillary RCC 36 pts enrolled Higher PFS & ORR with doublet Results of STELLAR-304, SAMETA & AXIPAP are pending! #ESMO26

PAPMET2 Ph2 trial initiated by @SWOG presented by @maughanonc at #ESMO26. Builds upon #PAPMET by adding atezolizumab to cabozantinib for pRCC. Small cohort given rare histological subtype but initial results promising: PFS 25 vs 10mo, ORR 47%, no PD as BOR. Results for ongoing #STELLAR304, #SAMETA & #PAXIPEM nccRCC and pRCC trials eagerly awaited @RWinayak

Thanks! The cooperative groups continue to conduct important studies. Glad to be a part of that process!